Pangen Biotech
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Pangen Biotech makes a biosimilar version of erythropoietin (EPO), a medicine that treats anemia in patients with chronic kidney disease, and supplies it to healthcare markets in South Korea, Malaysia, the Philippines, Saudi Arabia, and Thailand.
Hospitals and healthcare providers are the end users of its EPO products, which are approved and marketed under the brand names Erysaa and Panpotin in those countries. Listed on KOSDAQ, South Korea's tech and small-cap board, the company also runs a contract development and manufacturing (CDMO) business, producing biopharmaceuticals on behalf of other drug developers. Its proprietary cell-line and protein-expression technology, called PanGen CHO-TECH™, underpins both its own product pipeline and its CDMO services.
Summary is AI-generated and may contain errors · figures from DART filings
The company's proprietary PanGen CHO-TECH™ platform, a specialized protein-expression technology built on CHO cells, is the in-house capability that supports both its biosimilar products and its contract manufacturing business.
Pangen Biotech in five facts
What does Pangen Biotech do?
Pangen Biotech makes a biosimilar version of erythropoietin (EPO), a medicine that treats anemia in patients with chronic kidney disease, and supplies it to healthcare markets in South Korea, Malaysia, the Philippines, Saudi Arabia, and Thailand.
Where is Pangen Biotech listed and in which sector?
Pangen Biotech (Korean name: 팬젠) trades under KRX code 222110 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Pangen Biotech?
Its market capitalisation was US$49M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Pangen Biotech's latest annual revenue and operating profit?
For fiscal year 2025, Pangen Biotech reported revenue of US$10.1M, operating profit of US$1.1M and net income of US$1.5M, per its annual report on DART (data retrieved from DART on 2026-09-18). Revenue was down 8.6% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-18
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Supply contract signed
Pangen Biotech disclosed a supply contract with Korea Disease Control and Prevention Agency National Institute of Health, worth US$1.78M, about 20.46% of its recent annual revenue, running through Dec 2028.
Supply contract · Jun 22 - Early redemption of convertible bonds (incl. overseas CBs)Capital raise · Apr 20
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Pangen Biotech reported separate results for FY2025: revenue of US$9.24M (−8.56% year on year), operating profit of US$1.04M (+47.65% year on year) and net income of US$1.41M (+117.3% year on year).
Earnings · Feb 3